Compare ASTI & ALLR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ASTI | ALLR |
|---|---|---|
| Founded | 2005 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Semiconductors | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 28.6M | 25.6M |
| IPO Year | 2014 | 2021 |
| Metric | ASTI | ALLR |
|---|---|---|
| Price | $3.33 | $1.36 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | ★ $20.00 | $9.75 |
| AVG Volume (30 Days) | ★ 387.4K | 64.7K |
| Earning Date | 05-11-2026 | 05-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 70.23 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $10,398,149.00 | $320,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 163.25 | N/A |
| 52 Week Low | $1.40 | $0.77 |
| 52 Week High | $9.87 | $2.35 |
| Indicator | ASTI | ALLR |
|---|---|---|
| Relative Strength Index (RSI) | 44.85 | 60.37 |
| Support Level | $2.90 | $1.34 |
| Resistance Level | $4.68 | $1.42 |
| Average True Range (ATR) | 0.29 | 0.08 |
| MACD | 0.13 | 0.03 |
| Stochastic Oscillator | 63.27 | 63.86 |
Ascent Solar Technologies Inc is a solar technology company that manufactures and sells photovoltaic (PV) solar modules that are flexible, durable, and possess attractive power to weight and power to area performance. Its technology provides renewable power solutions to high-value production and specialty solar markets where traditional rigid solar panels are not suitable, including space power beaming, aerospace, satellites, near earth orbiting vehicles, fixed wing unmanned aerial vehicles (UAV), aquatic, terrestrial, and other weight-sensitive markets with transformational high quality, value added product applications. It operates in single PV segment that sells PV products and engineering services and currently, is selling it in North America.
Allarity Therapeutics Inc is a clinical-stage, precision medicine pharmaceutical company focused on developing novel anti-cancer therapeutics for patients with high unmet medical needs. The company is actively advancing the development of stenoparib, an orally available, small-molecule inhibitor for patients with advanced recurrent ovarian cancer. It is leveraging its proprietary Drug Response Predictor (DRP) technology to refine patient selection and improve clinical outcomes. The company operates as a single operating and reporting segment (developing a treatment for ovarian cancer) in two geographic areas: Denmark and the United States. It is focused on the clinical development of its lead program: Stenoparib, which is being co-developed with a drug specific DRP companion diagnostic.